Tags: Cancer | trebananib | ovarian cancer | chemotherapy drugs

Ovarian Cancer Drug Shows Promise

Wednesday, 12 Jun 2013 12:01 PM


Amgen Inc said on Wednesday that its trebananib treatment for ovarian cancer had reduced the risk of disease progression or death by 34 percent in a clinical trial.
 
The company said the drug had met its primary goal in the trial, which is the first of three for the new treatment.
 
Amgen said that while it was working on the primary analysis of overall survival for 2014, it saw a favorable survival trend in an interim analysis.
 
Shares in Amgen were up slightly $98.25 in Nasdaq morning trading.

© 2015 Thomson/Reuters. All rights reserved.

1Like our page
2Share
Health-News
Amgen Inc said on Wednesday that its trebananib treatment for ovarian cancer had reduced the risk of disease progression or death by 34 percent in a clinical trial. The company said the drug had met its primary goal in the trial, which is the first of three for the new...
trebananib,ovarian cancer,chemotherapy drugs
89
2013-01-12
 

The information presented on this website is not intended as specific medical advice and is not a substitute for professional medical treatment or diagnosis. Read Newsmax Terms and Conditions of Service.

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
© Newsmax Media, Inc.
All Rights Reserved